Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA) (DeLOS II)

This study has been completed.
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
ClinAssess, University of Leipzig Identifier:
First received: July 27, 2007
Last updated: June 1, 2015
Last verified: June 2015
The DeLOS II trial is a multicenter randomised phase II trial investigating a TP/5-Fluorouracil (TPF)-chemotherapy with or without cetuximab for Patients with only by laryngectomy operable carcinoma of the larynx/hypopharynx. Patients were divided in responder or non-responder after 4 weeks. Since August 2009 Responder receive TP with or without Cetuximab + radiation. (Until february 2009 Responder received TPF with or without Cetuximab + radiation.) Planned accrual is 85 patients per treatment arm. The primary study endpoint is a confirmatory proof of an adequate survival rate with a functionally larynx-conserving 2 years after randomisation.

Condition Intervention Phase
Squamous Cell Carcinoma of the Hypopharynx
Larynx Carcinoma
Radiation: Radiation
Drug: Cetuximab
Drug: Docetaxel
Drug: Cisplatin (TP)
Drug: 5-Fluorouracil (TPF) (only until Feb 2009)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomised Phase II Screening Study to be Used in an TP/TPF-chemotherapy (Short Induction) Before TP/TPF-induction, Radiotherapy With or Without Cetuximab in the Primary Therapy of the Only by Laryngectomy Operable Carcinoma of the Larynx/Hypopharynx

Resource links provided by NLM:

Further study details as provided by University of Leipzig:

Primary Outcome Measures:
  • Confirmatory proof of an adequate survival rate with a functionally larynx-conserving 2 years after randomisation [ Time Frame: LFS-rate 2 years after randomisation ]

Secondary Outcome Measures:
  • Descriptive analysis of the study arms concerning the secondary end criteria of the study [ Time Frame: LSF 2 years after randomisation ]
  • Explorative comparison of the study arms concerning the primary and secondary end criteria of the study [ Time Frame: LSF 2 years after randomisation ]

Enrollment: 180
Study Start Date: July 2007
Study Completion Date: February 2015
Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
TP + Radiation (TPF until Feb 2009)
Radiation: Radiation
Radiation start in week 11
Drug: Docetaxel
75 mg/m2 i.v. day 1 3 times
Other Name: Taxotere
Drug: Cisplatin (TP)
75 mg/m2 i.v. day 1 3 times
Drug: 5-Fluorouracil (TPF) (only until Feb 2009)
Only patients recruited until Feb 2009: 750 mg/m2 i.v. day 1-5, 3 times
Experimental: B
TP + Cetuximab + Radiation (TPF until Feb 2009)
Radiation: Radiation
Radiation start in week 11
Drug: Cetuximab
Day 1 400mg/m2 i.v. than weekly 250 mg/m2 i.v. for 16 weeks
Drug: Docetaxel
75 mg/m2 i.v. day 1 3 times
Other Name: Taxotere
Drug: Cisplatin (TP)
75 mg/m2 i.v. day 1 3 times
Drug: 5-Fluorouracil (TPF) (only until Feb 2009)
Only patients recruited until Feb 2009: 750 mg/m2 i.v. day 1-5, 3 times


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed, primary only with laryngectomy respectable squamous-cell carcinoma of the larynx or hypopharynx
  • T3-T4a carcinoma of the glottis
  • T2-T4a carcinoma of the supraglottic, only controllable by laryngectomy and if applicable by root of tongue segmental resection
  • T2-T4a carcinoma of the hypopharynx only controllable by laryngectomy (for example T2, post cricoidal) and hypopharynx segmental resection
  • N-status: cervical metastases (N0-N3) have to be rehabilitate by surgical procedures

    • Blood count: Leukocytes >3500/mm\3, Neutrophils > 1500/ mm\3, Thrombocytes > 8000/ mm\3
    • Clinical chemistry:
  • adequate renal function, defined by serum creatinine and urea not higher than 25% upper NL, creatinine-clearance > 60 ml/min/1,72 m\2
  • adequate hepatic function with SGOT, SGPT not higher than 50% and bilirubin not higher than upper NL
  • electrolytes at NL

    • anesthetic risk normal or low-grade elevated
    • age 18-75 years
    • written informed consent
    • effective contraception after individual advice for men and women if there is a possibility of reproductive potential (effective contraception are: oral contraception with estrogen and gestagen (no minipill), vaginal ring, contraception patch, estrogen free ovulation suppressors, hormone spiral with progesterone, injection for three month with depot gestagen, hormone releasing implantation (luteal hormone containing rod), abstinence or sterilization (vasectomy) of the male)

Exclusion Criteria:

  • primary cancer treatable by operational larynx -conserving procedures
  • distant metastases (M1-Status)
  • total tumor volume exceeding 80 ml or larynx skeleton punctuated with infiltration of surrounding soft tissues respectively the esophageal aditus (exclusive cartilage infiltration represents no exclusion criteria)
  • tumor-specific prior chemo or radiotherapy
  • metachronous or synchronous malignant tumor (exception basalioma) [in case of a controlled tumor of different localization with a non-treated interval over 5 years to the present therapy the patient can be included after consultation with the coordinating investigator]
  • life expectancy < 3 month
  • Karnofsky performance status < 70%
  • serious cardiopulmonary concomitant disease (cardiac insufficiency grade III and IV according NYHA status, myocardial infarction, angina pectoris, respiratory global insufficiency)
  • Chronic diseases with permanent-therapy (uncontrolled diabetes, active rheumatoid arthritis)
  • recurrent pneumonia, COPD GOLD stage <2, chronic inflammation of intestine or any other concomitant diseases, which disallow study participation in the opinion of the responsible physician
  • Other circumstances (contra-indications), which disallow treatment with Docetaxel, Cisplatin, 5-FU, Cetuximab or radiotherapy
  • Expected absent patient compliance
  • Periodic follow-up not possible (for example address outside germany)
  • Pregnant or breast-feeding woman
  • Absent or constricted legal capacity
  • Participation to another clinical trial with any investigational study within 30 days prior to study screening
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00508664

Universitätsklinik für HNO
Graz, Austria, 8036
Landeskrankenhaus Klagenfurt
Klagenfurt, Austria, A-9020
Allgemeines Krankenhaus der Stadt Wien
Vienna, Austria, 1090
Helios Klinikum Erfurt GmbH Klinik für HNO-Heilkunde, Plastische Operationen
Erfurt, Thüringen, Germany, 99089
Universitätsklinik Aachen
Aachen, Germany, 52074
Charité, Campus Benjamin Franklin
Berlin, Germany, 12200
Klinikum Neukölln, Vivantes GmbH
Berlin, Germany, 12351
Klinikum Bielefeld-Mitte
Bielefeld, Germany, 33604
Malteser Krankenhaus St. Anna gGmbH, HNO-Klinik
Duisburg, Germany, 47259
Klinikum Fulda gAG, Klinik für Hals-Nasen-Ohrenkrankheiten
Fulda, Germany, 36043
Medizinische Hochschule Hannover
Hannover, Germany, 30625
Klinikum Hannover Nordstadt
Hannover, Germany
Universitätsklinikum Heidelberg
Heidelberg, Germany, 69120
Universitätsklinikum Jena
Jena, Germany, 07743
St. Vincentius Kliniken
Karlsruhe, Germany
Klinikum Kassel GmbH
Kassel, Germany, 34125
Katholisches Klinikum Koblenz Marienhof
Koblenz, Germany, 56073
Universitätsklinik Köln
Köln, Germany, 50924
Universitätsklinikum Leipzig
Leipzig, Germany, 04103
Universtitätsklinikum Schleswig-Holstein
Lübeck, Germany, 23538
Klinikum Großhadern
München, Germany, 81377
Medizinische Fakultät der Westfälischen Wilhelms-Universität Münster
Münster, Germany, 48149
Südharz-Krankenhaus Nordhausen gGmbH
Nordhausen, Germany
Klinikum Ernst von Bergmann gGmbH
Potsdam, Germany, 14467
Universtitätsklinikum Regensburg
Regensburg, Germany
Klinikum Stuttgart Katharinenhospital, Klinik für HNO-Krankheiten
Stuttgart, Germany, 70174
Bayerischen Julius Maximillians-Universtät Würzburg
Würzburg, Germany, 97080
Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Andreas Dietz, Dr. med. University of Leipzig
  More Information

Responsible Party: ClinAssess, Prof. Dietz, Universität Leipzig, University of Leipzig Identifier: NCT00508664     History of Changes
Other Study ID Numbers: TP(F)+Radiation+/-Cetuximab
Study First Received: July 27, 2007
Last Updated: June 1, 2015

Keywords provided by University of Leipzig:
by laryngectomy operable carcinoma of the larynx and the hypopharynx

Additional relevant MeSH terms:
Carcinoma, Squamous Cell
Laryngeal Diseases
Laryngeal Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Squamous Cell
Respiratory Tract Diseases
Otorhinolaryngologic Diseases
Otorhinolaryngologic Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Respiratory Tract Neoplasms
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on May 22, 2017